

January to September 2026 Unaudited Interim Report of the Krka Group and Krka

CONTENTS

Introduction **3**
Krka Group January–September 2026 performance highlights 3
Krka and Krka Group highlights 4
Krka ID card 5
Krka Group at a glance 5
2026 Krka Group performance estimate 6
2027 Krka Group business plan 6

Business report **7**
Financial risks 7
Investor and share information 7
Krka Group performance analysis 9
Marketing and sales 12
Research and Development 18
Investments 19
Employees 20

Condensed consolidated financial statements of the Krka Group, with notes **21**
Consolidated statement of financial position of the Krka Group 21
Consolidated income statement of the Krka Group 22
Consolidated statement of other comprehensive income of the Krka Group 22
Consolidated statement of changes in equity of the Krka Group 23
Consolidated statement of cash flows of the Krka Group 25
Segment reporting of the Krka Group 26
Notes to consolidated financial statements of the Krka Group 27

Condensed financial statements of Krka, d. d., Novo mesto, with notes **33**
Statement of financial position of Krka, d. d., Novo mesto 33
Income statement of Krka, d. d., Novo mesto 34
Statement of other comprehensive income of Krka, d. d., Novo mesto 34
Statement of changes in equity of Krka, d. d., Novo mesto 35
Statement of cash flows of Krka, d. d., Novo mesto 37
Notes to financial statements of Krka, d. d., Novo mesto 38

Statement of compliance **44**

INTRODUCTION

The condensed consolidated financial statements of the Krka Group (hereinafter also the Group) and the condensed financial statements of Krka, d. d., Novo mesto (hereinafter also Krka, the Company, the controlling company, we, our, or us) for the periods January–September 2026 and January–September 2025 are unaudited. The financial statements for the year ended 31 December 2025 are audited. Krka has no authorised capital and no conditional increase in share capital.

We promptly disclose all material changes to the information contained in the listing prospectus of Krka through the electronic information dissemination systems SEOnet of the Ljubljana Stock Exchange and ESPI of the Polish Financial Supervision Authority. Reports on the business operations of the Krka Group and Krka, d. d. are available at www.krka.biz.

The Supervisory Board reviewed the unaudited business report of the Krka Group and Krka for the period January–September 2026 at its regular meeting on 11 November 2026.

Krka Group January–September 2026 performance highlights

- Krka Group revenue totalled €1,660.0 million, of which product sales accounted for 97%.
- Group revenue increased by 8% year on year.
- We generated 94% sales of products and services outside Slovenia. Export accounted for 96% of total product sales.
- Region East Europe recorded the highest sales, accounting for 36.7% of total Krka Group sales, and was followed by Region Central Europe and Region West Europe.
- The Krka Group generated EBIT of €455.5 million, up 24% year on year. EBIT margin was 27.4%. EBITDA amounted to €527.9 million, up 21% year on year. EBITDA margin was 31.8%.
- Krka Group net profit totalled €364.2 million, up 13% year on year, with net profit margin of 21.9%.
- As at 30 September 2026, the Krka share traded at €258.50 on the Ljubljana Stock Exchange, up 27% on year-end 2025. In the first nine months of 2026, we repurchased treasury shares in total of €31.1 million.
- We expanded our product portfolio with ten new products: nine prescription pharmaceuticals and one animal health product.
- The Krka Group allocated €87.3 million to investments, up 31% year on year.
- At the end of September 2026, the Krka Group had 13,307 employees on its payroll, up 1% on year-end 2025. Total headcount, including agency workers, stood at 13,358.

Krka and Krka Group highlights

	Krka Group			Krka		
€ thousand	Jan–Sep 2026	Jan–Sep 2025	Index	Jan–Sep 2026	Jan–Sep 2025	Index
Revenue	1,660,036	1,534,028	108	1,540,832	1,415,996	109
– Of which revenue from sales of products and services	1,652,775	1,529,127	108	1,300,758	1,224,414	106
Gross profit	1,009,859	884,852	114	942,922	815,727	116
Earnings before interest, tax, depreciation and amortisation (EBITDA)	527,942	436,734	121	493,037	400,008	123
Operating profit (EBIT)[1]	455,531	367,154	124	440,101	348,339	126
Profit before tax (EBT)	451,088	395,453	114	435,756	387,787	112
Net profit	364,221	323,654	113	354,574	317,985	112
R&D expenses	150,457	143,733	105	148,567	141,494	105
Investments	87,322	66,742	131	68,323	48,025	142

€ thousand	30 Sep 2026	31 Dec 2025	Index	30 Sep 2026	31 Dec 2025	Index
Non-current assets	1,091,491	1,059,759	103	1,091,834	1,058,622	103
Current assets	2,001,856	1,982,899	101	1,765,185	1,702,780	104
– Inventories	633,651	644,102	98	544,379	539,860	101
– Trade receivables	653,992	609,315	107	646,846	560,340	115
– Cash and cash equivalents	336,184	347,819	97	226,411	273,658	83
Equity	2,431,642	2,377,151	102	2,320,264	2,272,584	102
Non-current liabilities	168,048	165,213	102	136,000	132,921	102
Current liabilities	493,657	500,294	99	400,755	355,897	113
– Trade payables	150,932	124,654	121	210,009	160,231	131

Ratios	Jan–Sep 2026	Jan–Sep 2025	Jan–Sep 2026	Jan–Sep 2025
Gross profit margin	60.8%	57.7%	61.2%	57.6%
EBITDA margin	31.8%	28.5%	32.0%	28.2%
EBIT margin	27.4%	23.9%	28.6%	24.6%
EBT margin	27.2%	25.8%	28.3%	27.4%
Net profit margin (ROS)	21.9%	21.1%	23.0%	22.5%
Return on equity (ROE)[2]	20.2%	19.0%	20.6%	19.3%
Return on assets (ROA)[3]	15.8%	14.8%	16.8%	15.9%
Liabilities/Equity	0.272	0.287	0.231	0.230
R&D expenses/Revenue	9.1%	9.4%	9.6%	10.0%

Headcount	30 Sep 2026	31 Dec 2025	Index	30 Sep 2026	31 Dec 2025	Index
Balance at	13,307	13,236	101	7,771	7,733	100

Share information	Jan–Sep 2026	Jan–Sep 2025	Index
Total number of shares issued	32,793,448	32,793,448	100
Earnings per share (EPS) in €[4]	16.03	14.09	114
Closing price at the end of the period in €[5]	258.50	214.00	121
Price/Earnings ratio (P/E)	16.12	15.19	106
Book value in €[6]	74.15	70.29	105
Price/Book value (P/B)	3.49	3.04	115
Market capitalisation in € thousand (end of period)	8,477,106	7,017,798	121

[1] The difference between operating income and expenses
[2] Net profit, annualised/Average shareholders' equity in the period
[3] Net profit, annualised/Average total asset balance in the period
[4] Net profit attributable to majority equity holders of the Krka Group, annualised/Average number of shares issued in the period, excluding treasury shares
[5] Share price on the Ljubljana Stock Exchange
[6] Equity at the end of the period/Total number of shares issued

Krka ID card

Registered office Šmarješka cesta 6, 8501 Novo mesto, Slovenia

Telephone +386 7 331 21 11

E-mail info@krka.biz

Website www.krka.biz

Core business Manufacture of pharmaceutical preparations

Business classification code 21.200

Year established 1954

Registration entry 1/00097/00, District Court of Novo mesto, Slovenia

Tax number 82646716

VAT registration number SI82646716

Company ID number 5043611000

Share capital €54,732,264.71

Total number of shares issued 32,793,448 ordinary registered no-par value shares, KRKG stock symbol Krka shares have been listed on the Ljubljana Stock Exchange since 1997 under the KRKG stock symbol, and dual-listed on the Warsaw Stock Exchange since April 2012 under the KRK stock symbol.

Krka Group at a glance

The Krka Group comprises the controlling company, Krka, d. d., Novo mesto, Slovenia, the Slovenian subsidiary Terme Krka, d. o. o., Novo mesto, and 33 subsidiaries outside Slovenia.

The Krka Group develops, produces, markets, and sells human health products (prescription pharmaceuticals and non-prescription products), animal health products, and health resort and tourist services.

Production takes place at the controlling company in Slovenia and at subsidiaries in the Russian Federation, Poland, Croatia, and Germany. In addition to production, these subsidiaries, apart from Krka-Rus in the Russian Federation, engage in marketing and sales. In China, production takes place in leased production facilities. Other subsidiaries outside Slovenia market and/or sell Krka products, but do not engage in production.

Terme Krka, d. o. o., Novo mesto provides health resort and tourist services and operates through the following business units: Terme Dolenjske Toplice; Terme Šmarješke Toplice; Hoteli Otočec; and Talaso Strunjan. Terme Krka is also the majority owner of Golf Grad Otočec, d. o. o.

In 2024, Krka and Laurus Labs Ltd. from India established Krka Pharma Private Limited, a joint venture based in Hyderabad, India, in which Krka holds a 51% stake. The Krka Group accounts for the investment in the joint venture under the equity method.

2026 Krka Group performance estimate

- Full-year revenue is projected at €2,179 million, up 7% year on year. Estimated revenue exceeds the 2026 revenue target.
- The share of sales generated outside Slovenia is estimated at 94%.
- Prescription pharmaceuticals are set to remain the leading product category, accounting for 84% of total sales.
- Net profit is forecast at €439 million, up 9% year on year, outstripping the 2026 plan by €34 million.
- We plan to invest just under €115 million in in-house development, production, and infrastructure facilities, a €20 million increase on 2025.
- At the end of 2026, the Krka Group is expected to have 13,443 regular employees on payroll, up 2% year on year, of whom 42% are employed outside Slovenia.

2027 Krka Group business plan

- We plan revenue at €2,308 million, up €129 million or 6% on the 2026 revenue estimate.
- The share of sales generated outside Slovenia is estimated at 94%.
- Region East Europe is expected to generate the highest sales, followed by Region Central Europe, Region West Europe, Region South-East Europe, Region Slovenia, and Region Overseas Markets.
- We expect prescription pharmaceuticals to remain our leading product category, accounting for more than 83% of total sales.
- Net profit is projected at €474 million, up €35 million or 8% on the 2026 estimate.
- We plan to invest €141 million primarily in expansion and modernisation of production facilities and infrastructure, a €26 million increase on 2026.
- The total number of employees in Slovenia and abroad is projected to increase by 2%.

The 2027 business objectives derive from the *2026–2030 Krka Group Development Strategy* and are based on estimates, assessments, forecasts, and other available information. The Management Board believes these forecasts are reasonable. In the event of significant changes in the business environment, such as price erosion, increases in raw material prices, foreign exchange fluctuations in certain key currencies, or a decline in demand for pharmaceutical products, actual operating results may differ from those projected.

BUSINESS REPORT

Financial risks

Foreign exchange risk

Our key currency risk management policy remains to mitigate currency risk exposure by natural hedging. We also use financial instruments to a limited extent.

The Russian rouble continues to represent the largest Krka Group currency risk. Given the limited availability of suitable financial hedging instruments in international markets, we continued to rely primarily on natural hedging of Russian rouble exposure.

The Russian rouble depreciated by 1.8% against the euro from the beginning of the year to the end of September, while its average exchange rate against the euro increased by 4.3% year on year. In the first nine months of 2026, the Krka Group recorded foreign exchange loss from its long position in the Russian rouble, recognised in net financial result.

We continued to hedge the US dollar using financial instruments in the first nine months of 2026. Unlike exposure to other currencies, exposure to the US dollar arises from a surplus of liabilities over assets from regular business operations; in other words, the currency position is short. Exposure to the US dollar arises primarily from the purchase of raw and other materials.

From the beginning of the year to the end of the third quarter, the US dollar strengthened by 3.5% against the euro, while its average exchange rate against the euro decreased by 3.6% year on year.

Other currencies significant to our operations remained relatively stable in the first nine months of 2026.

Net foreign exchange result, comprising net foreign exchange gains and losses and derivative income and expenses, amounted to a loss of €9.7 million. The Krka Group recorded net financial result of -€4.4 million, reflecting foreign exchange result, interest income and expenses, and other financial income and expenses.

Credit risk

The Krka Group's main credit risk stems from trade receivables. The centralised credit control process at the Krka Group level includes all customers with credit limits exceeding €20,000. There were over 500 such customers at the end of Q3 2026, accounting for more than 95% of the Group's total trade receivables. Credit control for small customers is decentralised across the sales network and remains under the constant supervision of the controlling company.

Our credit risk management policy remained unchanged in the first nine months of 2026. At the end of this period, more than 90% of Krka Group trade receivables were insured with a credit insurance company.

By the end of Q3 2026, the total value of euro-denominated trade receivables was 7% higher than at the beginning of the year. The maturity structure of receivables remained stable. The ratio of overdue receivables to total trade receivables remained within acceptable limits at the end of Q3 2026.

Investor and share information

The Krka share price on the Ljubljana Stock Exchange rose by 27% in the first nine months of 2026 and stood at €258.50 on 30 September 2026. During this period, holdings of Slovenian retail investors, legal entities and institutional investors, as well as treasury shares, increased, while foreign investor holdings declined. At the end of September 2026, Krka had 50,269 shareholders.

Shareholder structure (%)

	30 Sep 2026	31 Dec 2025
Slovenian retail investors	41.8	41.7
Slovenski državni holding (SDH, Slovenian Sovereign Holding) and the Republic of Slovenia	16.2	16.2
Kapitalska družba, d. d. (KD, Pension Fund Management) and Prvi pokojninski sklad (PPS, First Pension Fund)	10.8	10.8
Slovenian legal entities and institutional investors	6.0	5.8
Foreign investors	17.4	18.1
Treasury shares	7.8	7.4
Total	**100.0**	**100.0**

In the first nine months of 2026, Krka acquired 127,978 treasury shares and held 2,562,805 treasury shares as at 30 September 2026, accounting for 7.815% of share capital.

Ten largest shareholders as at 30 September 2026


	Country	No. of shares	Equity stake (%)	Voting rights (%)
Kapitalska družba, d. d.	Slovenia	3,493,030	10.65	11.55
Slovenski državni holding, d. d.	Slovenia	2,949,876	9.00	9.76
Republic of Slovenia	Slovenia	2,366,424	7.22	7.83
OTP banka d.d.[1]	Croatia	1,505,798	4.59	4.98
Erste Group Bank AG[1]	Austria	903,512	2.76	2.99
Clearstream Europe AG[1]	Germany	836,966	2.55	2.77
Luka Koper, d. d.	Slovenia	433,970	1.32	1.44
InterCapital Securities Ltd.[1]	Croatia	365,754	1.12	1.21
Privredna banka Zagreb d.d.[1]	Croatia	324,930	0.99	1.07
State Street Bank and Trust Company[1]	USA	287,949	0.88	0.95
Total		**13,468,209**	**41.07**	**44.55**

[1] The shares are held in custody accounts with the above-listed banks and are owned by the banks' clients.

Equity stakes and voting rights of Management and Supervisory Board members as at 30 September 2026

	No. of shares	Equity stake (%)	Voting rights (%)
Management Board members			
Jože Colarič	22,500	0.069	0.074
Aleš Rotar	13,915	0.042	0.046
Vinko Zupančič	120	0.000	0.000
Milena Kastelic	505	0.002	0.002
Total Management Board members	**37,040**	**0.113**	**0.123**
Supervisory Board members			
Julijana Kristl	230	0.001	0.001
Mojca Osolnik Videmšek	617	0.002	0.002
Tomaž Sever	500	0.002	0.002
Total Supervisory Board members	**1,347**	**0.004**	**0.004**
Total Management and Supervisory Board members	**38,387**	**0.117**	**0.127**

Krka share trading in January–September 2026




As at 30 September 2026, Krka's market capitalisation on the Ljubljana Stock Exchange, including treasury shares, totalled €8.5 billion. The average daily trading volume of Krka shares during the period amounted to €1.2 million. Since April 2012, Krka shares have been dual-listed on the Warsaw Stock Exchange.

Krka Group performance analysis

Revenue

€ thousand	Jan–Sep 2026	Jan–Sep 2025	Index
Revenue from contracts with customers on sales of products and services	1,652,775	1,529,127	108
Revenue from contracts with customers on sales of materials, and other revenue	7,261	4,901	148
Total revenue	**1,660,036**	**1,534,028**	**108**
Other operating income	4,281	5,386	79
Financial income	15,980	47,020	34
Total income	**1,680,297**	**1,586,434**	**106**

Revenue by period




Expenses

€ thousand	Jan–Sep 2026	% of revenue	Jan–Sep 2025	% of revenue	Index
Cost of goods sold	650,177	39.2	649,176	42.3	100
Selling and distribution expenses	313,576	18.9	288,986	18.8	109
R&D expenses	150,457	9.1	143,733	9.4	105
General and administrative expenses	94,576	5.7	90,365	5.9	105
Total operating expenses	**1,208,786**	**72.9**	**1,172,260**	**76.4**	**103**
Financial expenses	20,423	1.2	18,721	1.2	109
Total expenses	**1,229,209**	**74.1**	**1,190,981**	**77.6**	**103**

Operating results

€ thousand	Jan–Sep 2026	Jan–Sep 2025	Index
Earnings before interest, tax, depreciation and amortisation (EBITDA)	527,942	436,734	121
Operating profit (EBIT)	455,531	367,154	124
Profit before tax (EBT)	451,088	395,453	114
Net profit	364,221	323,654	113

Net profit by period




Assets

€ thousand	30 Sep 2026	%	31 Dec 2025	%	Index
Non-current assets	**1,091,491**	**35.3**	**1,059,759**	**34.8**	**103**
Attributable to:					
– Property, plant and equipment	830,178	26.8	828,905	27.2	100
– Intangible assets	114,555	3.7	99,787	3.3	115
Current assets	**2,001,856**	**64.7**	**1,982,899**	**65.2**	**101**
Attributable to:					
– Inventories	633,651	20.5	644,102	21.2	98
– Trade receivables and other receivables	699,680	22.6	633,503	20.8	110
Total assets	**3,093,347**	**100.0**	**3,042,658**	**100.0**	**102**

Equity and liabilities

€ thousand	30 Sep 2026	%	31 Dec 2025	%	Index
Equity	**2,431,642**	**78.6**	**2,377,151**	**78.1**	**102**
Non-current liabilities	**168,048**	**5.4**	**165,213**	**5.4**	**102**
Attributable to:	138,551	4.5	135,188	4.4	102
– Provisions for post-employment benefits and other non-current employee benefits	130,052	4.2	126,324	4.2	103
– Provisions for lawsuits	8,112	0.3	8,245	0.3	98
– Other provisions	387	0.0	619	0.0	63
Current liabilities	**493,657**	**16.0**	**500,294**	**16.5**	**99**
– Trade payables	150,932	4.9	124,654	4.1	121
– Contract liabilities	170,405	5.5	191,984	6.3	89
– Other current liabilities	172,320	5.6	183,653	6.1	94
Total equity and liabilities	**3,093,347**	**100.0**	**3,042,658**	**100.0**	**102**

Performance ratios



Performance ratios are in line with the Krka Group's key strategic objectives.

Marketing and sales

In the first nine months of 2026, the Krka Group generated revenue of €1,660.0 million, of which revenue from contracts with customers on sales of products and services totalled €1,652.8 million. Sales in markets outside Slovenia totalled €1,548.7 million, accounting for 94% of total Krka Group sales of products and services.

Krka Group product and service sales by region

Sales increased in most markets and all sales regions, except in Region West Europe.

Product and service sales by region

€ thousand	Jan–Sep 2026	Jan–Sep 2025	Index
Region Slovenia	104,097	98,821	105
– % of total sales	*6.3*	*6.5*	
Region South-East Europe	235,583	218,220	108
– % of total sales	*14.3*	*14.3*	
Region East Europe	606,731	533,723	114
– % of total sales	*36.7*	*34.9*	
Region Central Europe	374,315	350,857	107
– % of total sales	*22.7*	*22.9*	
Region West Europe	266,805	272,389	98
– % of total sales	*16.1*	*17.8*	
Region Overseas Markets	65,244	55,117	118
– % of total sales	*3.9*	*3.6*	
Total	**1,652,775**	**1,529,127**	**108**

Region Slovenia

Sales of products and services in Region Slovenia, our domestic market, totalled €104.1 million in the first nine months of 2026. Product sales were valued at €62.2 million, while services generated €41.9 million sales.

Holding a 7.4% market share, we remained the leading pharmaceutical provider in Slovenia by sales value.

Products from our key therapeutic categories promoted in marketing campaigns contributed most substantially to sales, above all those for cardiovascular diseases; pain relief; the central nervous system; the gastrointestinal tract; and vitamins and minerals.

Among prescription pharmaceuticals for the treatment of cardiovascular diseases, statins were at the forefront, in particular Sorvasta (rosuvastatin) and Sorvitimb, our rosuvastatin/ezetimibe single-pill combination.

Of our antihypertensives, the perindopril-based products stood out, particularly the two single-pill combinations Amlewel (perindopril/amlodipine/indapamide) and Amlessa (perindopril/amlodipine), which recorded the highest sales growth. We bolstered recognition of our innovative single-pill combination Tolupind (telmisartan/indapamide). They have further strengthened Krka's leading market position and brand awareness in the antihypertensive market.

We also bolstered brand awareness of oral anticoagulants. Among them were two well-established medicines, Daxanlo (dabigatran) and Delianda (edoxaban) – the latter presented one of the highest sales increases – and the newly launched Xerdoxo (rivaroxaban), available in film-coated tablets in the 10 mg, 15 mg, and 20 mg strengths.

Our leading pain relievers were a NSAID Nalgesin Forte (naproxen), a non-opioid analgesic Algominal (metamizole), and an analgesic Daleron (paracetamol) 1000 mg.

We raised brand awareness of our antidepressant Dulsevia (duloxetine) and the antipsychotic Kventiax (quetiapine) from our central nervous system product group. We also increased the brand awareness of Vitamin D3 Krka 7000 IU (cholecalciferol), which is taken once per week.

Of our non-prescription products, we also enhanced the brand awareness of vitamins and minerals Magnezij Krka, our leading non-prescription product, followed by an analgesic Nalgesin S (naproxen). In September, we rolled out our Septabene soft-core lozenges with lemon-and-ginger flavour for quick and effective throat relief. The novel

product is expected to bolster the visibility of the entire Septabene brand. In Slovenia, we market lozenges in five flavours and a spray.

Sales of animal health products were driven by Floron (florfenicol), followed by Fypryst Combo (fipronil/S-methoprene) for protection against fleas and ticks, and a wide-spectrum parasiticide Milprazon (milbemycin/praziquantel). We expanded our animal health product range by adding Robexera (robenacoxib) chewable tablets for cats to the list.

Region South-East Europe

Product sales by market

€ thousand	Jan–Sep 2026	Jan–Sep 2025	Index
Romania	59,292	58,696	101
Croatia	41,973	39,087	107
Serbia	34,535	31,748	109
Bulgaria	27,147	24,963	109
North Macedonia	26,155	23,725	110
Bosnia and Herzegovina	23,878	21,543	111
Kosovo	8,954	8,231	109
Greece	6,886	3,808	181
Albania	3,386	3,245	104
Montenegro	3,376	3,173	106
Total	**235,583**	**218,220**	**108**

According to the latest data, our market share by volume reached 7.4%, and we were the most successful provider of generic prescription pharmaceuticals in the pharmacy segment in **Romania**. Atoris (atorvastatin), Co-Roswera (rosuvastatin/ezetimibe), Nolpaza (pantoprazole), Co-Prenessa (perindopril/indapamide), Roswera (rosuvastatin), Teotard (theophylline), Dulsevia (duloxetine), and Co-Amlessa (perindopril/amlodipine/indapamide) were our flagship products. We extended our product range with Xerdoxo (rivaroxaban) and Nolpaza Control (pantoprazole). Nalgesin (naproxen) and Bilobil (ginkgo leaf extract) were our flagship non-prescription products.

Antiparasitic products remained our best-selling animal health products, especially the Fypryst brand products and Selehold (selamectin). We added Robexera (robenacoxib) solution for injection and tablets for cats to our animal health products.

In **Croatia**, we remained the second most successful generic pharmaceutical company by sales of prescription pharmaceuticals in the pharmacy segment. The leading prescription pharmaceuticals were Emanera (esomeprazole), Atoris (atorvastatin), and Co-Dalneva (perindopril/amlodipine/indapamide). We also recorded sales growth with our new medicine Xerdoxo (rivaroxaban), Co-Roswera (rosuvastatin/ezetimibe), Delianda (edoxaban), Valomindo (valsartan/indapamide), and Delxora (tramadol/dexketoprofen), as well as with the tender product Meaxin (imatinib), and Abiraterone Krka (abiraterone). We added three newly launched products to our portfolio: Xerdoxo (rivaroxaban), Delxora (tramadol/dexketoprofen), and Bisonessa (bisoprolol/perindopril).

Nalgesin (naproxen) and Septolete Duo (benzydamine/cetylpyridinium chloride) recorded the strongest sales of non-prescription products. The Fypryst brand products and Robexera (robenacoxib) generated the strongest sales of animal health products. We added solution for injection and tablets for cats to the Robexera range.

Region East Europe

Product sales by market

€ thousand	Jan–Sep 2026	Jan–Sep 2025	Index
Russian Federation	372,131	315,303	118
Ukraine	82,653	72,189	114
Uzbekistan	39,722	44,610	89
Belarus	27,811	23,946	116
Kazakhstan	16,466	15,114	109
Mongolia	14,679	13,817	106
Moldova	14,272	13,105	109
Georgia	9,202	7,796	118
Armenia	9,030	7,071	128
Azerbaijan	8,139	7,821	104
Kyrgyzstan	6,684	6,476	103
Tajikistan	4,073	3,737	109
Turkmenistan	1,869	2,739	68
Total	**606,731**	**533,723**	**114**

Our product sales in the **Russian Federation** generated €372.1 million in the first nine months of the year, up 18% year on year. As per the latest available data from independent sources, we ranked first among international providers of generic medicines.

Prescription pharmaceuticals were the leading product group, accounting for 85% of overall country sales. Co-Perineva (perindopril/indapamide), Co-Dalneva (perindopril/amlodipine/indapamide), Duloxenta (duloxetine), Roxera Plus (rosuvastatin/ezetimibe), Vamloset (valsartan/amlodipine), Valsacor (valsartan), Roxera (rosuvastatin), Lorista H and Lorista HD (losartan/hydrochlorothiazide), Nolpaza (pantoprazole), and Lorista (losartan) generated the strongest sales. Roxera Plus (rosuvastatin/ezetimibe), Duloxenta (duloxetine), and Co-Perineva (perindopril/indapamide) recorded the highest absolute growth. In the third quarter of 2026, we successfully rolled out Dapafors (dapagliflozin), an important agent used for treating type 2 diabetes. We were one of the leading suppliers of prescription pharmaceuticals in the pharmacy segment and the leading provider of cardiovascular prescription pharmaceuticals.

Nalgesin (naproxen), the Herbion brand products used to alleviate cough, and Septolete Total (benzydamine/cetylpyridinium chloride) recorded the highest sales and growth of our non-prescription products. Selafort (selamectin), Milprazon (milbemycin/praziquantel), and Cladaxxa (amoxicillin/clavulanic acid) generated the strongest sales of our animal health products.

In the first nine months of 2026, the Krka-Rus production plant supplied over 70% of all Krka products sold in the Russian Federation.

As per the latest available data, we ranked first among foreign providers of medicines in **Ukraine**, with sales growth rate significantly outpacing market growth. Prescription pharmaceuticals remained the leading sales group. Co-Prenessa (perindopril/indapamide), Co-Amlessa (perindopril/amlodipine/indapamide), Telmista H (telmisartan/hydrochlorothiazide), and Co-Valsacor (valsartan/hydrochlorothiazide) generated the strongest sales. Non-prescription products that generated the highest sales were Nalgesin (naproxen), the Herbion brand products, and Septolete Total (benzydamine/cetylpyridinium chloride). The leading animal health products were Selafort (selamectin) and Milprazon (milbemycin/praziquantel).

In **Uzbekistan**, we remained the second largest provider of medicines by sales value according to the latest available data, outpacing market growth by 23 percentage points in sales volume of prescription pharmaceuticals. Our paramount prescription pharmaceuticals were Nolpaza (pantoprazole), Amlessa (perindopril/amlodipine), and Valodip (valsartan/amlodipine), while Septolete Total (benzydamine/cetylpyridinium chloride) and Pikovit headed the non-prescription product list.

Region Central Europe

Product sales by market

€ thousand	Jan–Sep 2026	Jan–Sep 2025	Index
Poland	187,077	178,087	105
Czechia	51,529	47,982	107
Hungary	45,642	39,745	115
Slovakia	34,402	32,188	107
Lithuania	28,678	28,295	101
Latvia	17,224	15,628	110
Estonia	9,763	8,932	109
Total	**374,315**	**350,857**	**107**

Poland remained our second largest individual market, recording 5% growth. Based on the latest data, we remained the fifth largest provider of generic medicines in the country. Sales were driven by prescription pharmaceuticals, most notably Atoris (atorvastatin), Roswera (rosuvastatin), Doreta (tramadol/paracetamol), Valsacor (valsartan), Co-Valsacor (valsartan/hydrochlorothiazide), and Coroswera (rosuvastatin/ezetimibe). Our other prescription pharmaceuticals that generated strong sales were Dulsevia (duloxetine), Emanera (esomeprazole), and Asentra (sertraline). The Septolete product brand and Septanazal (xylometazoline/dexpanthenol) remained best-selling non-prescription products, while Milprazon (milbemycin/praziquantel), Enroxil (enrofloxacin), and Cladaxxa (amoxicillin/clavulanic acid) generated the highest animal health product sales.

In **Czechia**, our second largest regional market, we recorded 7% year-on-year growth. Based on the latest data, we remained the fifth largest provider of generic medicines in the country. Sales were driven in particular by prescription pharmaceuticals, most notably Sorvasta (rosuvastatin), Atoris (atorvastatin), Pragiola (pregabalin), Nolpaza (pantoprazole), Elicea (escitalopram), and Lexaurin (bromazepam). Nalgesin S (naproxen) and the Septolete brand products were our paramount non-prescription products, while the Dehinel and Fypryst brand products remained key animal health products.

In **Hungary**, our third largest regional market by sales, we recorded 15% year-on-year sales growth, retaining the sixth place among providers of generic pharmaceuticals. Prescription pharmaceuticals generated the highest sales, in particular Co-Prenessa (perindopril/indapamide), Doreta (tramadol/paracetamol), Emozul (esomeprazole), Dulsevia (duloxetine), Roxera (rosuvastatin), Kventiax (quetiapine), Zyllt (clopidogrel), and Valsacor (valsartan). Our best-selling non-prescription products were Septanazal (xylometazoline/dexpanthenol), Septolete Extra (benzydamine/cetylpyridinium chloride), and Bilobil (ginkgo leaf extract). Milprazon (milbemycin/praziquantel) and the Fypryst brand products were the leading animal health products.

We retained the fourth place among providers of generic medicines in **Slovakia**. Year on year, we recorded 7% sales growth. Prescription pharmaceuticals generated the highest sales, in particular Amlessa (perindopril/amlodipine), Co-Prenessa (perindopril/indapamide), Atoris (atorvastatin), Co-Amlessa (perindopril/amlodipine/indapamide), Nolpaza (pantoprazole), Prenessa (perindopril), and Kventiax (quetiapine). Nalgesin S (naproxen), Flebaven (diosmin), and Nolpaza (pantoprazole) recorded the highest sales of non-prescription products, while the Fypryst and Dehinel brand products and Enroxil (enrofloxacin) sold best of animal health products.

Region West Europe

Product sales by market

€ thousand	Jan–Sep 2026	Jan–Sep 2025	Index
Germany	65,575	64,899	101
Nordic countries[1]	54,174	55,500	98
Portugal	29,711	28,663	104
Italy	19,624	21,155	93
United Kingdom	16,689	16,676	100
Spain	16,011	17,050	94
France	14,869	16,976	88
Ireland	11,198	10,885	103
Belgium	10,705	13,327	80
Netherlands	9,792	10,917	90
Austria	9,703	9,442	103
Other European countries	8,754	6,898	127
Total	**266,805**	**272,389**	**98**

[1] Denmark, Finland, Iceland, Norway, and Sweden

We recorded a slight year-on-year sales increase in **Germany**, which remained our largest regional market. Sales were driven by medicines for the treatment of cardiovascular diseases and the central nervous system, followed by oncology agents, and medicines for the gastrointestinal tract and metabolic disorders. Agents containing candesartan, atorvastatin, ramipril, and valsartan generated the strongest sales. We remained the leading supplier of the tramadol/paracetamol single-pill combinations and cyproterone-based medicines, and the innovative single-pill combination of valsartan and indapamide. We successfully entered the market with a tramadol/dexketoprofen single-pill combination and perindopril in combination with amlodipine and indapamide.

Sales of our non-prescription products increased by 19%, primarily on the back of products containing acetylsalicylic acid and the benzydamine/cetylpyridinium chloride combination products marketed under the Septolete brand. We increased sales of our animal health products by 11%. The milbemycin/praziquantel tablet wormer recorded the strongest sales.

Region Overseas Markets

Product sales by market

€ thousand	Jan–Sep 2026	Jan–Sep 2025	Index
Far East and Africa	34,059	26,776	127
China	15,052	8,927	169
Middle East	13,585	17,950	76
Americas	2,547	1,464	174
Total	**65,244**	**55,117**	**118**

In the first nine months of 2026, our Region Overseas Market increased year-on-year sales by 18%. Sales increased in all markets except in the **Middle East**.

Product and service sales by group

Product and service sales by group

€ thousand	Jan–Sep 2026	Jan–Sep 2025	Index
Prescription pharmaceuticals	1,396,566	1,274,060	110
– % of total sales	*84.5*	*83.3*	
Non-prescription products	119,314	124,319	96
– % of total sales	*7.2*	*8.1*	
Animal health products	94,976	88,830	107
– % of total sales	*5.8*	*5.8*	
Health resort and tourist services	41,919	41,918	100
– % of total sales	*2.5*	*2.8*	
Total	**1,652,775**	**1,529,127**	**108**

Prescription pharmaceuticals

Sales of our prescription pharmaceuticals increased in Region East Europe (up 17%), Region Slovenia (up 13%), Region South-East Europe (up 9%), Region Central Europe (up 7%), and Region Overseas Markets (up 20%), while they declined in Region West Europe (down 4%).

As of our four largest markets, year-on-year sales increased in the Russian Federation (up 23%), Ukraine (up 16%), and Poland (up 5%), while they levelled off with the last year's figure in Germany. We also recorded sales growth in other major markets, in Hungary (up 16%), Slovenia (up 13%), Czechia (up 9%), Slovakia (up 8%), Croatia and Serbia (up 7%), and Romania (up 2%).

The top ten prescription pharmaceuticals by sales were product groups containing perindopril (Prenessa*, Co-Prenessa*, Amlessa*, Co-Amlessa*, Bi-Prenessa*, Pixoroso*, Roxiper*, Roxampex*); valsartan (Valsacor*, Co-Valsacor*, Wamlox*, Valtricom*, Valomindo*, Valarox*); rosuvastatin (Roswera*, Co-Roswera*); atorvastatin (Atoris*, Co-Atoris*); pantoprazole (Nolpaza*); losartan (Lorista*, Lorista H*, Lorista HD*, Tenloris*); telmisartan (Tolura*, Tolucombi*, Telassmo*, Tolutris*, Tolurindo*); duloxetine (Dulsevia*); esomeprazole (Emanera*), and tramadol (Tadol*, Doreta*, Delanxara*).

Product groups containing rosuvastatin, perindopril, telmisartan, atorvastatin, and duloxetine contributed the most to sales growth.

We extended our product portfolio with newly launched medicines: (a) an immunosuppressant containing apremilast for the treatment of psoriasis and psoriatic arthritis in Germany, the Nordic countries, the United Kingdom, Belgium, France, Austria, Slovakia, Ireland, and the Netherlands; (b) a single-pill antihypertensive Bi-Prenessa* (bisoprolol/perindopril) in the Russian Federation, Latvia, Bulgaria, Poland, Slovakia, and Croatia; (c) a single-pill combination for the treatment of hyperlipidaemia Co-Pitipix* (pitavastatin/ezetimibe) in Bulgaria and Portugal; and (d) a single-pill analgesic Delanxara* (tramadol/dexketoprofen) in Poland, Portugal, Croatia, Hungary, Czechia, Germany, Latvia, Estonia, and Moldova.

Non-prescription products

Year-on-year sales of non-prescription products increased in Region South-East Europe (up 1%), levelled off with the last year's figure in Region Overseas Markets, while they decreased in all other regions: Region West Europe (down 1%), Region Slovenia (down 2%), Region Central Europe (down 2%), and Region East Europe (down 8%). A mild flu and cold season in the first half of the year decreased the use of seasonal products, resulting in sales decline across all regions.

Products sold under the Nalgesin*, Septolete*, Herbion*, Septanazal, and Bilobil* brands generated the highest sales.

Animal health products

Sales of animal health products increased in Region West Europe (up 12%), Region Slovenia (up 9%), Region South-East Europe (up 9%), Region Central Europe (up 8%), and Region East Europe (up 2%).

The combination of milbemycin and praziquantel (Milprazon*), fipronil (Fypryst*, Fypryst Combo*), selamectin (Selehold*), the combination of amoxicillin and clavulanic acid (Cladaxxa*), and the combination of pyrantel and praziquantel (Dehinel*, Dehinel Plus*) generated the strongest sales.

We rolled out Dehispot* (praziquantel/emodepside) spot-on solution for cats, a completely new addition to our portfolio of antiparasitics, in Germany, the United Kingdom, France, Italy, Belgium, Slovenia, Poland, Czechia, Portugal, Slovakia, Hungary, the Nordic countries, Lithuania, Latvia, Bulgaria, North Macedonia, the Russian Federation, and Ukraine.

Health resort and tourist services

Our subsidiary Terme Krka recorded over 250,000 overnight stays in the first nine months of 2026, matching sales in the same period last year. Talaso Strunjan recorded nearly 92,700 overnight stays, the highest of our resorts. Our other health resorts followed in this order: Terme Šmarješke Toplice with 85,400; Terme Dolenjske Toplice with 57,000; and Hoteli Otočec with over 15,200 overnight stays. Most guests came from Slovenia, accounting for 87% of overnight stays, while our foreign guests primarily came from Italy, Austria, and Germany.

Products marketed under different product brand names or the Krka trademark in individual markets are marked with asterisk (*).

Research and Development

In the first nine months of 2026, we expanded our product range with ten new products, including nine new prescription pharmaceuticals and one new veterinary medicine for companion animals. We finalised over 500 registration procedures for new and already established products in several markets.

Prescription pharmaceuticals

In the first nine months, we concluded marketing authorisation procedures for nine prescription medicines, while marketing authorisations were granted for already established medicines in new markets.

We obtained first marketing authorisations for two single-pill antidiabetic combinations, **Mempoglyn*** (empagliflozin/metformin) and **Lymerexa*** (linagliptin/metformin). The two agents in film-coated tablets combine two active substances with synergistic modes of action, providing a modern and comprehensive approach to the treatment of type 2 diabetes, and allowing for patient-tailored therapies. We expanded our cardiovascular portfolio by obtaining marketing authorisations for **Co-Pitavador*** (pitavastatin/ezetimibe), a single-pill combination indicated for treatment of patients with combined hyperlipidaemia.

In one of our key therapeutic areas, central nervous system diseases, marketing authorisation was granted for **Acazanian** (cariprazine) hard capsules, a new medicine used to treat schizophrenia. Marketing authorisations were also granted for two reformulated medicines: **Asentra** (sertraline) film-coated tablets used to treat depression and anxiety disorders, and **Dulsevia*** (duloxetine) gastro-resistant capsules, in some countries marketed as **Loxentia**, used in various therapeutic areas, but primarily for treating mental health conditions such as depression and anxiety and relieving peripheral diabetic neuralgia in adults.

We obtained marketing authorisations for our two new cardiovascular agents in China, **bisoprolol/amlodipine** combination tablets and **edoxaban** film-coated tablets. A marketing authorisation was granted for a new strength of the single-pill combination of **empagliflozin** and **metformin** film-coated tablets used to treat diabetes, tailored to the needs of the Chinese market.

New marketing authorisations in additional markets were granted for our established products. Among them, in the European Union markets, are **Roxera Plus** (rosuvastatin/ezetimibe), the single-pill combination used to treat combined hyperlipidaemia, and analgesic medicine containing **naproxen**, both available as film-coated tablets. We obtained additional marketing authorisations under the decentralised procedure for **Emlygexa*** (empagliflozin) film-coated tablets primarily used to treat diabetes.

In eastern European countries, additional marketing authorisations were granted for the single-pill combination **Nalgesin Duo** (naproxen/paracetamol) film-coated tablets used to treat mild to moderate pain, antidiabetic agents **Dapafors** (dapagliflozin) and **Dapafors Met** (dapagliflozin/metformin), and **Dapafors Sita** (dapagliflozin/sitagliptin) film-coated tablets. In the cardiovascular therapeutic area, marketing authorisations were granted for the single-pill combination **Valsacor INDA** (valsartan/indapamide) modified-release tablets used for lowering high blood pressure, **Valkubiks** (valsartan/sacubitril) film-coated tablets used to treat heart failure and hypertension, and for

the contemporary anticoagulant **Aboxoma** (apixaban) film-coated tablets. We also obtained marketing authorisation for the single-pill combination **Atoris Plus** (atorvastatin/ezetimibe) film-coated tablets indicated for the treatment of hyperlipidaemia.

Marketing authorisations granted in markets in south-eastern Europe include single-pill combinations **Mexdagry** (dapagliflozin/metformin) and **Dagraduo** (dapagliflozin/sitagliptin) film-coated tablets used to treat high blood sugar. In the cardiovascular therapeutic area, marketing authorisations were granted for the single-pill combination **Tolurindo** (telmisartan/indapamide) modified-release tablets and **Tolutris** (telmisartan/amlodipine/hydrochlorothiazide) tablets used to treat high blood pressure, and the single-pill combination **Valkubit** (sacubitril/valsartan) in the form of film-coated tablets used to treat heart failure. Additional marketing authorisations were granted for two contemporary anticoagulants, **Daxanlo** (dabigatran) capsules and **Aboxoma** (apixaban) film-coated tablets.

Several new marketing authorisations were also granted in our overseas markets. Notable marketing authorisations included those granted for **Roswera** (rosuvastatin) film-coated tablets for treating hyperlipidaemia, **Prenewel** (perindopril/indapamide) and **Prenessa Neo** (perindopril) tablets used to lower high blood pressure and **Itoroxx** (etoricoxib) film-coated tablets used for the relief of pain and inflammation symptoms in the musculoskeletal system diseases. New marketing authorisations granted for products from the DPP-4 inhibitor group broadened our antidiabetic agent portfolio.

Non-prescription products

We extended our portfolio of consumer health products by obtaining marketing authorisations for already established brands in additional markets. They included **Septolete Total Lemon-and-Ginger Flavoured Lozenges** (benzydamine/cetylpyridinium chloride) and **Septolete Total Cola-Flavoured Lozenges** (benzydamine/cetylpyridinium chloride) for relieving pain and inflammation in the oral cavity and throat, and **Herbion Iceland Moss** lozenges for relieving irritation of the mucosa in the throat and mouth, as well as the associated dry cough. Also, **Herbion Ivy Syrup** indicated to help expectoration was approved for marketing in another country.

Animal health products

We expanded the range of animal health products for companion animals with marketing authorisation for our new product **Robexera** (robenacoxib) chewable tablets for cats, marketed as **Rogiola** in certain countries. It is indicated for the control of pain and inflammation associated with musculoskeletal diseases and for the relief of moderate pain and inflammation after surgery.

We received marketing authorisations in additional markets for several established products. Among them are **Dehispot** (praziquantel/emodepside) spot-on solution indicated for the treatment and prevention of internal parasitic infections in cats and **Marinia** (maropitant) solution for injection, marketed as **Arocenia** in certain countries, which is used to treat and prevent nausea and vomiting in dogs and cats. Several new approvals for veterinary medicines used to treat companion animals were obtained also in overseas markets.

Products marketed under different product brand names or the Krka trademark in individual markets are marked with asterisk (*).

Investments

In the first nine months of 2026, the Krka Group allocated €87.3 million to investments, of which €68.3 million was allocated to the controlling company.

The upgrades at the Notol plant in Novo mesto, Slovenia, are designed to ensure reliable operations over the next 20 years. We plan to expand production capacity by constructing an extension to the solid dosage production plant. We successfully carried out preparations for the logistics system upgrade due for completion in 2027. We also intend to increase production capacity by installing additional equipment at Notol 2, another production plant in Novo mesto.

We completed the investment in additional capacities for tabletting mixture preparation, granulation, and logistics at the Solid Dosage Products Plant in Novo mesto, and launched a new project to increase production output and enhance manufacturing flexibility.

We installed a new suspension inspection line and finished building an extension for a new production line for sterile solutions at the Sterile Products Department in Novo mesto, thereby significantly enhancing production volumes.

At the Ločna site, we completed equipping the newly constructed seven-storey multi-purpose building and obtained the occupancy permit.

Work is in progress at the Bršljin Department in Novo mesto, Slovenia, to increase the production and packaging capacities for products for veterinary use. We also expect to boost the capacity for packaging tablets for veterinary use and spot-on solutions in the existing facility.

We increased the production capacity at the Ljutomer plant in Slovenia. Construction of an automated high-bay warehouse and an expansion of the plant are under way.

We completed construction of the technically and technologically advanced waste water treatment plant in Krško, Slovenia. Pre-treatment has been in operation since September. We also commissioned the remaining phases of the biological treatment process, and the plant is currently in trial operation.

We are currently increasing production capacity at the production and distribution centre in Jastrebarsko, Croatia.

In China, we set up product manufacturing operations to support the animal health programme. A filling and packaging line was installed and qualified.

Construction of research and production facilities for oncology products and solid dosage forms is underway at Krka Pharma Private Limited, a joint venture in Hyderabad, India.

Employees

At the end of September 2026, the Krka Group employed 13,307 persons, of whom 5,539 or 42% worked outside Slovenia. Of all Krka Group employees, 48% held at least a university degree, while 207 held doctoral degrees.

Krka Group employees by education

	30 Sep 2026		31 Dec 2025	
	Headcount	%	Headcount	%
PhD	207	1.5	202	1.5
MSc	375	2.8	392	3.0
University education	5,756	43.2	5,697	43.0
Higher professional education	2,326	17.5	2,265	17.1
Vocational college education	368	2.8	369	2.8
Secondary school education	3,123	23.5	3,161	23.9
Other	1,152	8.7	1,150	8.7
Total	**13,307**	**100.0**	**13,236**	**100.0**

We continue to attract new talented employees by awarding scholarships. At the end of September, Krka had 59 scholarship holders, primarily pharmacy and chemistry students. We also offer scholarships to exceptional students from other fields that might be of interest to us.

Our personnel development and succession planning system ensure that key professional and managerial positions are occupied by Krka Group employees.

We also invest in personnel development and skills. Employees in Slovenia and abroad acquire additional knowledge through training programmes, covering their respective professional fields as well as quality assurance, leadership, information technology, and personal development. They also participate in foreign language courses. We deliver most educational programmes in-house and tailor them to employee needs, technological processes, market situations, and development requirements of the Krka Group. We update the programmes regularly and introduce new forms of education adapted to the contemporary approaches to work.

In the first nine months of 2026, we offered educational support to 118 employees enrolled in part-time studies, including 26 at the postgraduate level.

Krka is also included in the national vocational qualification (NVQ) system. Between 2004 and the end of September 2026, we awarded 2,189 NVQ certificates to Krka employees for four vocational qualifications. At the end of September 2026, 77 Krka employees were included in obtaining a national vocational qualification.

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS OF THE KRKA GROUP, WITH NOTES

Consolidated statement of financial position of the Krka Group

€ thousand	30 Sep 2026	31 Dec 2025	Index
Assets			
Property, plant and equipment	830,178	828,905	100
Intangible assets	114,555	99,787	115
Investments in joint ventures	14,751	15,213	97
Loans	37,466	25,115	149
Investments	19,406	20,060	97
Deferred tax assets	73,874	69,469	106
Other non-current assets	1,261	1,210	104
Total non-current assets	**1,091,491**	**1,059,759**	**103**
Inventories	633,651	644,102	98
Contract assets	609	602	101
Trade receivables	653,992	609,315	107
Other receivables	45,688	24,188	189
Loans	85,154	99,585	86
Investments	246,578	257,288	96
Cash and cash equivalents	336,184	347,819	97
Total current assets	**2,001,856**	**1,982,899**	**101**
Total assets	**3,093,347**	**3,042,658**	**102**
Equity			
Share capital	54,732	54,732	100
Treasury shares	-256,163	-225,047	114
Reserves	275,302	249,022	111
Retained earnings	2,337,775	2,279,945	103
Total equity attributable to the holders of the controlling company	**2,411,646**	**2,358,652**	**102**
Non-controlling interests	19,996	18,499	108
Total equity	**2,431,642**	**2,377,151**	**102**
Liabilities			
Provisions	138,551	135,188	102
Deferred income	5,152	5,351	96
Lease liabilities	13,810	14,011	99
Deferred tax liabilities	10,535	10,663	99
Total non-current liabilities	**168,048**	**165,213**	**102**
Provisions	6,287	27,494	23
Trade payables	150,932	124,654	121
Borrowings	0	3	0
Lease liabilities	4,643	4,347	107
Income tax payables	30,081	33,263	90
Contract liabilities	170,405	191,984	89
Other current liabilities	131,309	118,549	111
Total current liabilities	**493,657**	**500,294**	**99**
Total liabilities	**661,705**	**665,507**	**99**
Total equity and liabilities	**3,093,347**	**3,042,658**	**102**

Consolidated income statement of the Krka Group

€ thousand	Jan–Sep 2026	Jan–Sep 2025	Index
Revenue	**1,660,036**	**1,534,028**	**108**
– Revenue from contracts with customers	1,656,781	1,531,187	108
– Other revenue	3,255	2,841	115
Cost of goods sold	-650,177	-649,176	100
Gross profit	**1,009,859**	**884,852**	**114**
Other operating income	4,281	5,386	79
Selling and distribution expenses	-313,576	-288,986	109
– Whereof net impairments and write-offs of receivables	794	-2,357	
R&D expenses	-150,457	-143,733	105
General and administrative expenses	-94,576	-90,365	105
Operating profit	**455,531**	**367,154**	**124**
Financial income	15,980	47,020	34
Financial expenses	-20,423	-18,721	109
Net financial result	**-4,443**	**28,299**	
Profit before tax	**451,088**	**395,453**	**114**
Income tax expense	-86,867	-71,799	121
Net profit	**364,221**	**323,654**	**113**
Attributable to:			
– Equity holders of the controlling company	**364,215**	322,927	113
– Non-controlling interests	6	727	1
Basic earnings per share[1] (€)	**12.02**	**10.56**	**114**
Diluted earnings per share[2] (€)	**12.02**	**10.56**	**114**

[1] Net profit/Average number of shares issued in the period, excluding treasury shares

[2] All shares issued by the company are ordinary shares, hence the diluted earnings per share ratio equalled basic earnings per share.

Consolidated statement of other comprehensive income of the Krka Group

€ thousand	Jan–Sep 2026	Jan–Sep 2025	Index
Net profit	**364,221**	**323,654**	**113**
Other comprehensive income for the period			
Other comprehensive income reclassified to profit or loss at a future date			
Translation reserve	-2,836	34,658	
Net other comprehensive income reclassified to profit or loss at a future date	**-2,836**	**34,658**	
Other comprehensive income that will not be reclassified to profit or loss at a future date			
Change in fair value of financial assets	-653	-705	93
Deferred tax effect	144	155	93
Net other comprehensive income that will not be reclassified to profit or loss at a future date	**-509**	**-550**	**93**
Total other comprehensive income for the period (net of tax)	**-3,345**	**34,108**	
Total comprehensive income for the period (net of tax)	**360,876**	**357,762**	**101**
Attributable to:			
– Equity holders of the controlling company	359,379	358,879	100
– Non-controlling interests	1,497	-1,117	

Consolidated statement of changes in equity of the Krka Group

€ thousand	Share capital	Treasury shares	Reserves						Retained earnings			Total equity attributable to the holders of the controlling company	Non-controlling interests	Total equity
			Reserves for treasury shares	Share premium	Legal reserves	Statutory reserves	Fair value reserve	Translation reserve	Other profit reserves	Retained earnings from previous periods	Profit for the period			
Balance at 1 Jan 2026	**54,732**	**-225,047**	**225,047**	**105,897**	**14,990**	**30,000**	**-6,579**	**-120,333**	**1,679,151**	**259,114**	**341,680**	**2,358,652**	**18,499**	**2,377,151**
Net profit	**0**	**0**	**0**	**0**	**0**	**0**	**0**	**0**	**0**	**0**	**364,215**	**364,215**	**6**	**364,221**
Total other comprehensive income for the period (net of tax)	**0**	**0**	**0**	**0**	**0**	**0**	**-526**	**-4,310**	**0**	**0**	**0**	**-4,836**	**1,491**	**-3,345**
Total comprehensive income for the period (net of tax)	**0**	**0**	**0**	**0**	**0**	**0**	**-526**	**-4,310**	**0**	**0**	**364,215**	**359,379**	**1,497**	**360,876**
Transactions with owners, recognised in equity														
Formation of other profit reserves under the resolution of the AGM	0	0	0	0	0	0	0	0	58,526	-58,526	0	0	0	0
Transfer of previous periods' profit to retained earnings	0	0	0	0	0	0	0	0	0	341,680	-341,680	0	0	0
Repurchase of treasury shares	0	-31,116	0	0	0	0	0	0	0	0	0	-31,116	0	-31,116
Formation of reserves for treasury shares	0	0	31,116	0	0	0	0	0	0	0	-31,116	0	0	0
Dividends paid	0	0	0	0	0	0	0	0	0	-275,269	0	-275,269	0	-275,269
Total transactions with owners, recognised in equity	**0**	**-31,116**	**31,116**	**0**	**0**	**0**	**0**	**0**	**58,526**	**7,885**	**-372,796**	**-306,385**	**0**	**-306,385**
Balance at 30 Sep 2026	**54,732**	**-256,163**	**256,163**	**105,897**	**14,990**	**30,000**	**-7,105**	**-124,643**	**1,737,677**	**266,999**	**333,099**	**2,411,646**	**19,996**	**2,431,642**

€ thousand	Share capital	Treasury shares	Reserves						Retained earnings			Total equity attributable to the holders of the controlling company	Non-controlling interests	Total equity
			Reserves for treasury shares	Share premium	Legal reserves	Statutory reserves	Fair value reserve	Translation reserve	Other profit reserves	Retained earnings from previous periods	Profit for the period			
Balance at 1 Jan 2025	**54,732**	**-163,491**	**163,491**	**105,897**	**14,990**	**30,000**	**-11,362**	**-166,701**	**1,620,098**	**238,545**	**331,984**	**2,218,183**	**19,601**	**2,237,784**
Net profit	**0**	**0**	**0**	**0**	**0**	**0**	**0**	**0**	**0**	**0**	**322,927**	**322,927**	**727**	**323,654**
Total other comprehensive income for the period (net of tax)	**0**	**0**	**0**	**0**	**0**	**0**	**-549**	**36,501**	**0**	**0**	**0**	**35,952**	**-1,844**	**34,108**
Total comprehensive income for the period (net of tax)	**0**	**0**	**0**	**0**	**0**	**0**	**-549**	**36,501**	**0**	**0**	**322,927**	**358,879**	**-1,117**	**357,762**
Transactions with owners, recognised in equity														
Formation of other profit reserves under the resolution of the AGM	0	0	0	0	0	0	0	0	59,053	-59,053	0	0	0	0
Transfer of previous periods' profit to retained earnings	0	0	0	0	0	0	0	0	0	331,984	-331,984	0	0	0
Repurchase of treasury shares	0	-39,890	0	0	0	0	0	0	0	0	0	-39,890	0	-39,890
Formation of reserves for treasury shares	0	0	39,890	0	0	0	0	0	0	0	-39,890	0	0	0
Dividends paid	0	0	0	0	0	0	0	0	0	-250,611	0	-250,611	0	-250,611
Total transactions with owners, recognised in equity	**0**	**-39,890**	**39,890**	**0**	**0**	**0**	**0**	**0**	**59,053**	**22,320**	**-371,874**	**-290,501**	**0**	**-290,501**
Balance at 30 Sep 2025	**54,732**	**-203,381**	**203,381**	**105,897**	**14,990**	**30,000**	**-11,911**	**-130,200**	**1,679,151**	**260,865**	**283,037**	**2,286,561**	**18,484**	**2,305,045**

Consolidated statement of cash flows of the Krka Group

€ thousand	Jan–Sep 2026	Jan–Sep 2025
CASH FLOWS FROM OPERATING ACTIVITIES		
Net profit	**364,221**	**323,654**
Adjustments for:	**165,232**	**188,990**
– Amortisation/Depreciation	72,411	69,580
– Net foreign exchange gains and losses	357	27,638
– Net write-offs and allowances for inventories	14,405	12,263
– Net impairments and write-offs of receivables	-794	2,357
– Investment income	-17,406	-14,585
– Investment expenses	291	10,000
– Income on financing activities	-6	-3
– Interest expense and other financial expenses	9,107	9,941
– Income tax expense	86,867	71,799
Operating profit before changes in net current assets	**529,453**	**512,644**
Change in trade receivables	-62,393	-64,140
Change in inventories	-3,954	-31,374
Change in trade payables	6,354	22,572
Change in provisions	-21,322	774
Change in deferred income	-199	-218
Change in other current liabilities	13,013	12,876
Income tax paid	-97,839	-71,059
Net cash flow from operating activities	**363,113**	**382,075**
CASH FLOWS FROM INVESTING ACTIVITIES		
Interest received	7,113	8,673
Dividends received	53	44
Proceeds from sale of property, plant and equipment	3,030	2,538
Acquisition of property, plant and equipment	-83,857	-66,829
Acquisition of intangible assets	-5,391	-4,370
Acquisition of interest in joint ventures	0	-9,234
Proceeds from non-current loans	1,471	2,261
Payments for non-current loans	-24,598	-3,726
Net proceeds from current loans	27,281	4,650
Proceeds from sale of non-current investments	38	20,299
Payments for acquisition of non-current investments	-89	-32
Proceeds from sale of current investments	310,000	395,000
Payments for acquisition of current investments	-294,920	-396,155
Proceeds from derivatives	2,889	49
Payments for derivatives	-281	-2,504
Net cash flow from investing activities	**-57,261**	**-49,336**
CASH FLOWS FROM FINANCING ACTIVITIES		
Interest paid	-5,053	-6,325
Net payments for current borrowings	-3	0
Lease liabilities paid	-4,157	-3,669
Dividends and other profit shares paid	-275,269	-251,962
Repurchase of treasury shares	-31,116	-39,890
Net cash flow from financing activities	**-315,598**	**-301,846**
Net decrease/increase in cash and cash equivalents	**-9,746**	**30,893**
Cash and cash equivalents at beginning of year	347,819	344,895
Effect of changes in foreign exchange rates on cash held	-1,889	-5,237
Closing balance of cash and cash equivalents	**336,184**	**370,551**

Segment reporting of the Krka Group

€ thousand	European Union		South-Eastern Europe		Eastern Europe		Total segment reporting		Other		Eliminations		Total	
	Jan–Sep 2026	Jan–Sep 2025	Jan–Sep 2026	Jan–Sep 2025	Jan–Sep 2026	Jan–Sep 2025	Jan–Sep 2026	Jan–Sep 2025	Jan–Sep 2026	Jan–Sep 2025	Jan–Sep 2026	Jan–Sep 2025	Jan–Sep 2026	Jan–Sep 2025
Revenue from sales to non-group customers	**857,802**	**827,176**	**100,304**	**91,679**	**606,805**	**533,792**	**1,564,911**	**1,452,647**	**95,125**	**81,381**			**1,660,036**	**1,534,028**
Revenue from sales to intragroup customers	**305,158**	**335,822**	**63,178**	**56,569**	**663,774**	**549,759**	**1,032,110**	**942,150**	**14,471**	**15,139**	**-1,046,581**	**-957,289**	**0**	**0**
Total revenue	**1,162,960**	**1,162,998**	**163,482**	**148,248**	**1,270,579**	**1,083,551**	**2,597,021**	**2,394,797**	**109,596**	**96,520**	**-1,046,581**	**-957,289**	**1,660,036**	**1,534,028**
Other operating income	3,658	3,222	66	24	484	688	4,208	3,934	73	1,452			4,281	5,386
Operating expenses	-666,902	-689,280	-64,764	-60,545	-397,628	-359,991	-1,129,294	-1,109,816	-79,492	-62,444			-1,208,786	-1,172,260
Intragroup operating expenses, including elimination of profits	-305,158	-335,822	-63,178	-56,569	-663,774	-549,759	-1,032,110	-942,150	-14,471	-15,139	1,046,581	957,289	0	0
Operating profit	**194,558**	**141,118**	**35,606**	**31,158**	**209,661**	**174,489**	**439,825**	**346,765**	**15,706**	**20,389**	**0**	**0**	**455,531**	**367,154**
Interest income	6,453	7,025	2	1	1,476	1,087	7,931	8,113	497	759			8,428	8,872
Intragroup interest income	1,844	1,600	0	0	0	0	1,844	1,600	1	0	-1,845	-1,600	0	0
Interest expense	-387	-277	-12	-9	1,679	-187	1,280	-473	-9	-9			1,271	-482
Intragroup interest expense	-1,844	-1,600	0	0	0	0	-1,844	-1,600	-1	0	1,845	1,600	0	0
Net financial result	**6,845**	**6,783**	**-297**	**-448**	**-11,913**	**25,816**	**-5,365**	**32,151**	**922**	**-3,852**			**-4,443**	**28,299**
Income tax expense	-39,306	-30,257	-6,526	-6,115	-38,701	-32,690	-84,533	-69,062	-2,334	-2,737			-86,867	-71,799
Net profit	**162,097**	**117,644**	**28,783**	**24,595**	**159,047**	**167,615**	**349,927**	**309,854**	**14,294**	**13,800**	**0**	**0**	**364,221**	**323,654**
Investments	83,685	60,987	331	411	3,300	4,768	87,316	66,166	6	576			87,322	66,742
Depreciation of property, plant and equipment	42,286	42,149	1,677	1,607	16,714	15,582	60,677	59,338	2,729	2,331			63,406	61,669
Depreciation of right-of-use assets	2,898	2,576	121	106	634	517	3,653	3,199	99	70			3,752	3,269
Amortisation of intangible assets	3,011	2,864	278	236	1,741	1,363	5,030	4,463	223	179			5,253	4,642
	30 Sep 2026	**31 Dec 2025**	**30 Sep 2026**	**31 Dec 2025**	**30 Sep 2026**	**31 Dec 2025**	**30 Sep 2026**	**31 Dec 2025**	**30 Sep 2026**	**31 Dec 2025**	**30 Sep 2026**	**31 Dec 2025**	**30 Sep 2026**	**31 Dec 2025**
Total assets	**2,124,844**	**2,178,925**	**91,701**	**86,724**	**726,891**	**655,519**	**2,943,436**	**2,921,168**	**149,911**	**121,490**			**3,093,347**	**3,042,658**
Non-current assets exclusive of deferred tax assets	872,766	862,295	8,085	6,756	93,092	88,492	973,943	957,543	43,674	32,747			1,017,617	990,290
Total liabilities	**394,658**	**399,923**	**25,462**	**24,925**	**199,802**	**205,694**	**619,922**	**630,542**	**41,783**	**34,965**			**661,705**	**665,507**

The Krka Group reports by geographical segments. Revenue generated by individual segments is presented by customers' geographical location. The data are calculated based on revenue and expenses, and on assets and liabilities, attributable to individual Krka Group markets. Eliminations relate to transactions between the controlling company and its subsidiaries, as well as between subsidiaries.

Notes to consolidated financial statements of the Krka Group

Costs by nature

€1,208,786 thousand

€ thousand	Jan–Sep 2026	Jan–Sep 2025	Index
Cost of goods and materials	397,786	403,186	99
Cost of services	193,828	187,507	103
Employee benefits expense	519,256	469,202	111
Amortisation and depreciation	72,411	69,580	104
Net write-offs and allowances for inventories	14,405	12,263	117
Net impairments and write-offs of receivables	-794	2,357	
Other operating expenses	35,830	32,277	111
Total costs	**1,232,722**	**1,176,372**	**105**
Change in the value of inventories of finished products and work in progress	-23,936	-4,112	582
Total	**1,208,786**	**1,172,260**	**103**

Employee benefits

€519,256 thousand

€ thousand	Jan–Sep 2026	Jan–Sep 2025	Index
Gross wages and salaries and continued pay	400,246	362,474	110
Social security contributions	31,217	25,269	124
Pension insurance contributions	54,465	50,396	108
Payroll tax	730	649	112
Post-employment benefits and other non-current employee benefits	5,379	5,507	98
Other employee benefits expense	27,219	24,907	109
Total employee benefits	**519,256**	**469,202**	**111**

Other operating expenses

€35,830 thousand

€ thousand	Jan–Sep 2026	Jan–Sep 2025	Index
Grants and assistance for humanitarian and other purposes	1,809	1,593	114
Environmental protection expenditures	5,267	4,508	117
Other taxes and levies	24,682	21,352	116
Loss on sale and write-offs of property, plant and equipment and intangible assets	271	1,138	24
Other operating expenses	3,801	3,686	103
Total other operating expenses	**35,830**	**32,277**	**111**

Other levies include various taxes and levies on pharmaceuticals, as well as fees paid to medical representatives in individual countries for carrying out promotional activities.

Financial income and expenses

€ thousand	Jan–Sep 2026	Jan–Sep 2025	Index
Net foreign exchange gains	0	33,992	0
Interest income	8,428	8,872	95
Derivative income	3,451	49	7,043
– Realised revenue	2,889	49	5,896
– Fair value change	562	0	
Income from other financial instruments	4,055	4,021	101
– Realised revenue	3,956	5,878	67
– Fair value change	99	-1,857	
Dividend income	52	44	118
Share of profit/loss from equity-accounted investments	-12	39	
Other financial income	6	3	200
Total financial income	**15,980**	**47,020**	**34**
Net foreign exchange losses	-12,884	0	
Interest expense	1,271	-482	
– Interest paid	1,848	-4	
– Interest expense on lease liabilities	-577	-478	121
Derivative expenses	-281	-8,777	3
– Realised expenses	-281	-2,504	11
– Fair value change	0	-6,273	0
Other financial expenses	-8,529	-9,462	90
Total financial expenses	**-20,423**	**-18,721**	**109**
Net financial result	**-4,443**	**28,299**	

Income tax expense €86,867 thousand

Current income tax amounted to €91,252 thousand, representing 20.2% of profit before tax. Taking into account deferred tax of -€4,782 thousand and other income-based taxes of €397 thousand, tax expense recognised in the income statement totalled €86,867 thousand. The effective tax rate was 19.3%.

Property, plant and equipment €830,178 thousand

€ thousand	30 Sep 2026	31 Dec 2025	Index
Land	68,088	66,178	103
Buildings	343,365	348,112	99
Equipment	318,580	327,022	97
Property, plant and equipment being acquired	82,382	69,733	118
Right-of-use assets	17,763	17,860	99
Total property, plant and equipment	**830,178**	**828,905**	**100**

The value of property, plant, and equipment accounted for 27% of the Krka Group balance sheet total. See the 'Investments' section in the business report for details on major investments of Krka.

Intangible assets — €114,555 thousand

€ thousand	30 Sep 2026	31 Dec 2025	Index
Goodwill	42,644	42,644	100
Trademark	30,782	31,435	98
Concessions, trademarks and licences	26,771	16,768	160
Other intangible assets	5,868	6,709	87
– Long-term deferred operating costs	51	121	42
– Development-related projects	3,884	4,564	85
– Emission coupons	1,933	2,024	96
Intangible assets being acquired	8,490	2,231	381
Total intangible assets	**114,555**	**99,787**	**115**

Loans — €122,620 thousand

€ thousand	30 Sep 2026	31 Dec 2025	Index
Non-current loans	**37,466**	**25,115**	**149**
– Loans to joint ventures	21,136	0	
– Loans to others	16,330	25,115	65
Current loans	**85,154**	**99,585**	**86**
– Portion of non-current loans maturing next year	2,532	12,022	21
– Loans to others	11,377	2,632	432
– Deposits granted to banks	68,000	83,001	82
– Current interest receivable	3,245	1,930	168
Total loans	**122,620**	**124,700**	**98**

Investments — €265,984 thousand

€ thousand	30 Sep 2026	31 Dec 2025	Index
Non-current investments	**19,406**	**20,060**	**97**
– Investments at fair value through OCI (equity instruments)	19,406	20,060	97
Current investments including derivatives	**246,578**	**257,288**	**96**
– Investments at fair value through profit or loss	246,263	257,288	96
– Derivatives	315	0	
Total investments	**265,984**	**277,348**	**96**

Investments at fair value through OCI comprised €1,772 thousand of investments in shares and interests in companies in Slovenia (end of 2025: €1,558 thousand), and €17,634 thousand of investments in shares and interests in companies outside Slovenia (end of 2025: €18,502 thousand).

The decrease in investments at fair value through profit or loss of €11,025 thousand comprised treasury bill acquisitions totalling €298,875 thousand, disposals of treasury bills totalling €310,000 thousand, and treasury bill revaluation gain totalling €100 thousand.

Inventories — €633,651 thousand

€ thousand	30 Sep 2026	31 Dec 2025	Index
Materials	239,553	254,813	94
Work in progress	139,646	122,076	114
Finished products	179,589	185,581	97
Merchandise	45,711	50,485	91
Advances for inventories	29,152	31,147	94
Total inventories	**633,651**	**644,102**	**98**

Trade and other receivables €699,680 thousand

€ thousand	30 Sep 2026	31 Dec 2025	Index
Current trade receivables	653,992	609,315	107
Current receivables due from others	45,688	24,188	189
Total receivables	**699,680**	**633,503**	**110**

Cash and cash equivalents €336,184 thousand

€ thousand	30 Sep 2026	31 Dec 2025	Index
Cash in hand	42	51	82
Bank balances	336,142	347,768	97
Total cash and cash equivalents	**336,184**	**347,819**	**97**

Bank balances included a deposit of €266,251 thousand with a maturity of up to 90 days (31 December 2025: €286,403 thousand).

Equity €2,431,642 thousand

€ thousand	30 Sep 2026	31 Dec 2025	Index
Share capital	54,732	54,732	100
Treasury shares	-256,163	-225,047	114
Reserves	275,302	249,022	111
– Reserves for treasury shares	256,163	225,047	114
– Share premium	105,897	105,897	100
– Legal reserves	14,990	14,990	100
– Statutory reserves	30,000	30,000	100
– Fair value reserve	-7,105	-6,579	108
– Translation reserve	-124,643	-120,333	104
Retained earnings	2,337,775	2,279,945	103
Total equity attributable to the holders of the controlling company	**2,411,646**	**2,358,652**	**102**
Non-controlling interests	19,996	18,499	108
Total equity	**2,431,642**	**2,377,151**	**102**

Provisions €144,838 thousand

€ thousand	30 Sep 2026	31 Dec 2025	Index
Non-current provisions	**138,551**	**135,188**	**102**
Provisions for lawsuits	8,112	8,245	98
Provisions for post-employment benefits	107,714	105,314	102
Provisions for other non-current employee benefits	22,338	21,010	106
Other provisions	387	619	63
Current provisions	**6,287**	**27,494**	**23**
Total provisions	**144,838**	**162,682**	**89**

Deferred income — €5,152 thousand

€ thousand	30 Sep 2026	31 Dec 2025	Index
Grants received from the European Regional Development Fund and the budget of the Republic of Slovenia intended for the production of pharmaceuticals in the new Notol 2 plant	481	520	93
Grants received from the budget for the Dolenjske and Šmarješke Toplice health resorts and Golf Grad Otočec	2,953	2,979	99
Grants received from the European Regional Development Fund (Farma GRS)	1,119	1,243	90
Property, plant and equipment received free of charge	2	15	13
Emission coupons	6	10	60
Subsidy for purchase of joinery	86	86	100
Subsidy for upgrading trucks	66	35	189
Subsidy for electricity production from renewable energy installations	439	463	95
Total deferred income	**5,152**	**5,351**	**96**

Trade payables — €150,932 thousand

€ thousand	30 Sep 2026	31 Dec 2025	Index
Current trade payables	**150,932**	**124,654**	**121**
Payables to joint ventures	28	0	
Payables to domestic suppliers	52,061	46,763	111
Payables to foreign suppliers	98,843	77,891	127
Total trade payables	**150,932**	**124,654**	**121**

Current contract liabilities — €170,405 thousand

€ thousand	30 Sep 2026	31 Dec 2025	Index
Refund liabilities	**158,939**	**184,479**	**86**
– Bonuses and volume rebates	157,352	182,401	86
– Rights of return	1,587	2,078	76
Contract liabilities	**11,466**	**7,505**	**153**
– Deferred income	1,222	1,212	101
– Advances from other customers	10,244	6,293	163
Total current contract liabilities	**170,405**	**191,984**	**89**

Other current liabilities — €131,309 thousand

€ thousand	30 Sep 2026	31 Dec 2025	Index
Payables to employees – gross salaries, other receipts and charges	113,837	105,656	108
Derivatives	0	247	0
Other	17,472	12,646	138
Total other current liabilities	**131,309**	**118,549**	**111**

Fair value

€ thousand	30 Sep 2026		31 Dec 2025	
	Carrying amount	Fair value	Carrying amount	Fair value
Non-current financial assets				
Loans	37,466		25,115	
Investments at fair value through OCI (equity instruments)	19,406	19,406	20,060	20,060
Current financial assets				
Loans	85,154		99,585	
Investments at fair value through profit or loss	246,263	246,263	257,288	257,288
Derivatives	315	315	0	0
Trade receivables	653,992		609,315	
Cash and cash equivalents	336,184		347,819	
Non-current financial liabilities				
Lease liabilities	-13,810		-14,011	
Current financial liabilities				
Borrowings	0		-3	
Derivatives	0	0	-247	-247
Lease liabilities	-4,643		-4,347	
Trade payables to suppliers and joint ventures, excluding advances	-150,932		-124,654	
Contract liabilities excluding advances	-157,352		-182,401	
Other liabilities excluding amounts owed to the State, to employees, and advances	-4,455		-4,809	
Total	**1,047,588**	**265,984**	**1,028,710**	**277,101**

In terms of fair value, assets and liabilities are classified into three levels:

- Level 1 – assets at market price;
- Level 2 – assets not classified within level 1 and the value of which is determined directly or indirectly based on observable market data;
- Level 3 – assets, the value of which cannot be determined using observable market data.

Assets at fair value

€ thousand	30 Sep 2026				31 Dec 2025			
	Level 1	Level 2	Level 3	Total	Level 1	Level 2	Level 3	Total
Assets at fair value								
Investments at fair value through OCI (equity instruments)	18,019	0	1,387	19,406	18,673	0	1,387	20,060
Investments at fair value through profit or loss	246,263	0	0	246,263	257,288	0	0	257,288
Derivatives	0	0	315	315	0	0	0	0
Total assets at fair value	**264,282**	**0**	**1,702**	**265,984**	**275,961**	**0**	**1,387**	**277,348**

CONDENSED FINANCIAL STATEMENTS OF KRKA, D. D., NOVO MESTO, WITH NOTES

Statement of financial position of Krka, d. d., Novo mesto

€ thousand	30 Sep 2026	31 Dec 2025	Index
Assets			
Property, plant and equipment	610,289	611,845	100
Intangible assets	40,398	24,363	166
Investments in subsidiaries	354,265	355,265	100
Investments in joint ventures	16,575	16,574	100
Loans	48,215	25,504	189
Investments	19,405	20,059	97
Deferred tax assets	2,027	4,347	47
Other non-current assets	660	665	99
Total non-current assets	**1,091,834**	**1,058,622**	**103**
Inventories	544,379	539,860	101
Trade receivables	646,846	560,340	115
Other receivables	21,337	11,125	192
Loans	79,634	60,509	132
Investments	246,578	257,288	96
Cash and cash equivalents	226,411	273,658	83
Total current assets	**1,765,185**	**1,702,780**	**104**
Total assets	**2,857,019**	**2,761,402**	**103**
Equity			
Share capital	54,732	54,732	100
Treasury shares	-256,163	-225,047	114
Reserves	401,784	371,177	108
Retained earnings	2,119,911	2,071,722	102
Total equity	**2,320,264**	**2,272,584**	**102**
Liabilities			
Provisions	127,839	123,912	103
Deferred income	2,201	2,363	93
Lease liabilities	5,960	6,646	90
Total non-current liabilities	**136,000**	**132,921**	**102**
Provisions	4,171	18,671	22
Trade payables	210,009	160,231	131
Borrowings	48,997	34,376	143
Lease liabilities	1,567	1,717	91
Income tax payables	24,066	26,872	90
Contract liabilities	19,932	23,772	84
Other current liabilities	92,013	90,258	102
Total current liabilities	**400,755**	**355,897**	**113**
Total liabilities	**536,755**	**488,818**	**110**
Total equity and liabilities	**2,857,019**	**2,761,402**	**103**

Income statement of Krka, d. d., Novo mesto

€ thousand	Jan–Sep 2026	Jan–Sep 2025	Index
Revenue	**1,540,832**	**1,415,996**	**109**
– Revenue from contracts with customers	1,532,158	1,409,393	109
– Other revenue	8,674	6,603	131
Cost of goods sold	-597,910	-600,269	100
Gross profit	**942,922**	**815,727**	**116**
Other operating income	2,145	1,802	119
Selling and distribution expenses	-274,868	-249,351	110
– Whereof net impairments and write-offs of receivables	613	-2,533	
R&D expenses	-148,567	-141,494	105
General and administrative expenses	-81,531	-78,345	104
Operating profit	**440,101**	**348,339**	**126**
Financial income	14,862	52,594	28
Financial expenses	-19,207	-13,146	146
Net financial result	**-4,345**	**39,448**	
Profit before tax	**435,756**	**387,787**	**112**
Income tax expense	-81,182	-69,802	116
Net profit	**354,574**	**317,985**	**112**
Basic earnings per share[1] (€)	**11.71**	**10.40**	**113**
Diluted earnings per share[2] (€)	**11.71**	**10.40**	**113**

[1] Net profit/Average number of shares issued in the period, excluding treasury shares

[2] All shares issued by the company are ordinary shares, hence the diluted earnings per share ratio equalled basic earnings per share.

Statement of other comprehensive income of Krka, d. d., Novo mesto

€ thousand	Jan–Sep 2026	Jan–Sep 2025	Index
Net profit	**354,574**	**317,985**	**112**
Other comprehensive income for the period			
Other comprehensive income that will not be reclassified to profit or loss at a future date			
Change in fair value of financial assets	-653	-705	93
Deferred tax effect	144	155	93
Net other comprehensive income that will not be reclassified to profit or loss at a future date	**-509**	**-550**	**93**
Total other comprehensive income for the period (net of tax)	**-509**	**-550**	**93**
Total comprehensive income for the period (net of tax)	**354,065**	**317,435**	**112**

Statement of changes in equity of Krka, d. d., Novo mesto

€ thousand	Share capital	Treasury shares	Reserves					Retained earnings			Total equity
			Reserves for treasury shares	Share premium	Legal reserves	Statutory reserves	Fair value reserve	Other profit reserves	Retained earnings from previous periods	Profit for the period	
Balance at 1 Jan 2026	**54,732**	**-225,047**	**225,047**	**105,897**	**14,990**	**30,000**	**-4,757**	**1,679,151**	**58,755**	**333,816**	**2,272,584**
Net profit	**0**	**0**	**0**	**0**	**0**	**0**	**0**	**0**	**0**	**354,574**	**354,574**
Total other comprehensive income for the period (net of tax)	**0**	**0**	**0**	**0**	**0**	**0**	**-509**	**0**	**0**	**0**	**-509**
Total comprehensive income for the period (net of tax)	**0**	**0**	**0**	**0**	**0**	**0**	**-509**	**0**	**0**	**354,574**	**354,065**
Transactions with owners, recognised in equity											
Formation of other profit reserves under the resolution of the AGM	0	0	0	0	0	0	0	58,526	-58,526	0	0
Transfer of previous periods' profit to retained earnings	0	0	0	0	0	0	0	0	333,816	-333,816	0
Repurchase of treasury shares	0	-31,116	0	0	0	0	0	0	0	0	-31,116
Formation of reserves for treasury shares	0	0	31,116	0	0	0	0	0	0	-31,116	0
Dividends paid	0	0	0	0	0	0	0	0	-275,269	0	-275,269
Total transactions with owners, recognised in equity	**0**	**-31,116**	**31,116**	**0**	**0**	**0**	**0**	**58,526**	**21**	**-364,932**	**-306,385**
Balance at 30 Sep 2026	**54,732**	**-256,163**	**256,163**	**105,897**	**14,990**	**30,000**	**-5,266**	**1,737,677**	**58,776**	**323,458**	**2,320,264**

€ thousand	Share capital	Treasury shares	Reserves					Retained earnings			Total equity
			Reserves for treasury shares	Share premium	Legal reserves	Statutory reserves	Fair value reserve	Other profit reserves	Retained earnings from previous periods	Profit for the period	
Balance at 1 Jan 2025	**54,732**	**-163,491**	**163,491**	**105,897**	**14,990**	**30,000**	**-9,435**	**1,620,098**	**73,879**	**296,190**	**2,186,351**
Net profit	**0**	**0**	**0**	**0**	**0**	**0**	**0**	**0**	**0**	**317,985**	**317,985**
Total other comprehensive income for the period (net of tax)	**0**	**0**	**0**	**0**	**0**	**0**	**-550**	**0**	**0**	**0**	**-550**
Total comprehensive income for the period (net of tax)	**0**	**0**	**0**	**0**	**0**	**0**	**-550**	**0**	**0**	**317,985**	**317,435**
Transactions with owners, recognised in equity											
Formation of other profit reserves under the resolution of the AGM	0	0	0	0	0	0	0	59,053	-59,053	0	0
Transfer of previous periods' profit to retained earnings	0	0	0	0	0	0	0	0	296,190	-296,190	0
Repurchase of treasury shares	0	-39,890	0	0	0	0	0	0	0	0	-39,890
Formation of reserves for treasury shares	0	0	39,890	0	0	0	0	0	0	-39,890	0
Dividends paid	0	0	0	0	0	0	0	0	-250,611	0	-250,611
Total transactions with owners, recognised in equity	**0**	**-39,890**	**39,890**	**0**	**0**	**0**	**0**	**59,053**	**-13,474**	**-336,080**	**-290,501**
Balance at 30 Sep 2025	**54,732**	**-203,381**	**203,381**	**105,897**	**14,990**	**30,000**	**-9,985**	**1,679,151**	**60,405**	**278,095**	**2,213,285**

Statement of cash flows of Krka, d. d., Novo mesto

€ thousand	Jan–Sep 2026	Jan–Sep 2025
CASH FLOWS FROM OPERATING ACTIVITIES		
Net profit	**354,574**	**317,985**
Adjustments for:	**132,130**	**136,149**
– Amortisation/Depreciation	52,936	51,669
– Net foreign exchange gains and losses	-327	3,324
– Net write-offs and allowances for inventories	9,078	7,114
– Net impairments and write-offs of receivables	-613	2,533
– Investment income	-15,356	-12,587
– Investment expenses	137	9,929
– Income on financing activities	-5	-2
– Interest expense and other financial expenses	5,098	4,367
– Income tax expense	81,182	69,802
Operating profit before changes in net current assets	**486,704**	**454,134**
Change in trade receivables	-96,115	-77,894
Change in inventories	-13,597	-21,773
Change in trade payables	47,316	27,155
Change in non-current provisions	568	1,413
Change in deferred income	-162	-159
Change in other current liabilities	-12,498	4,984
Income tax paid	-81,524	-56,454
Net cash flow from operating activities	**330,692**	**331,406**
CASH FLOWS FROM INVESTING ACTIVITIES		
Interest received	5,835	5,883
Dividends received	53	44
Proportionate profit of subsidiaries	1,098	1,904
Proceeds from sale of property, plant and equipment	1,994	1,421
Acquisition of property, plant and equipment	-64,477	-47,697
Acquisition of intangible assets	-5,224	-3,932
Refunds of subsequent contributions to subsidiaries	1,000	0
Acquisition of interest in joint ventures	0	-9,234
Proceeds from non-current loans	1,799	1,765
Payments for non-current loans	-24,405	-3,444
Net payments for/proceeds from current loans	-18,110	548
Proceeds from sale of non-current investments	33	20,276
Payments for acquisition of non-current investments	-28	-22
Proceeds from sale of current investments	310,000	395,000
Payments for acquisition of current investments	-294,920	-396,155
Proceeds from derivatives	2,889	49
Payments for derivatives	-281	-2,504
Net cash flow from investing activities	**-82,744**	**-36,098**
CASH FLOWS FROM FINANCING ACTIVITIES		
Interest paid	-972	-1,135
Net proceeds from current borrowings	14,048	23,977
Lease liabilities paid	-1,525	-1,139
Dividends and other profit shares paid	-275,269	-251,962
Repurchase of treasury shares	-31,116	-39,890
Net cash flow from financing activities	**-294,834**	**-270,149**
Net decrease/increase in cash and cash equivalents	**-46,886**	**25,159**
Cash and cash equivalents at beginning of year	273,658	238,183
Effect of changes in foreign exchange rates on cash held	-361	-817
Closing balance of cash and cash equivalents	**226,411**	**262,525**

Notes to financial statements of Krka, d. d., Novo mesto

Costs by nature

€1,102,876 thousand

€ thousand	Jan–Sep 2026	Jan–Sep 2025	Index
Cost of goods and materials	401,614	394,919	102
Cost of services	270,469	253,649	107
Employee benefits expense	372,413	337,954	110
Amortisation and depreciation	52,936	51,669	102
Net write-offs and allowances for inventories	9,078	7,114	128
Net impairments and write-offs of receivables	-613	2,533	
Other operating expenses	26,622	23,283	114
Total costs	**1,132,519**	**1,071,121**	**106**
Change in the value of inventories of finished products and work in progress	-29,643	-1,662	1,784
Total	**1,102,876**	**1,069,459**	**103**

Employee benefits

€372,413 thousand

€ thousand	Jan–Sep 2026	Jan–Sep 2025	Index
Gross wages and salaries and continued pay	286,544	261,147	110
Social security contributions	24,318	18,728	130
Pension insurance contributions	35,419	33,424	106
Post-employment benefits and other non-current employee benefits	4,978	5,190	96
Other employee benefits expense	21,154	19,465	109
Total employee benefits	**372,413**	**337,954**	**110**

Other operating expenses

€26,622 thousand

€ thousand	Jan–Sep 2026	Jan–Sep 2025	Index
Grants and assistance for humanitarian and other purposes	1,646	1,472	112
Environmental protection expenditures	3,469	2,924	119
Other taxes and levies	19,098	15,577	123
Loss on sale and write-offs of property, plant and equipment and intangible assets	115	1,054	11
Other operating expenses	2,294	2,256	102
Total other operating expenses	**26,622**	**23,283**	**114**

Other levies include various taxes and levies on pharmaceuticals, as well as fees paid to medical representatives in individual countries for carrying out promotional activities.

Financial income and expenses

€ thousand	Jan–Sep 2026	Jan–Sep 2025	Index
Net foreign exchange gains	0	40,520	0
Interest income	6,198	6,042	103
Derivative income	3,451	49	7,043
– Realised revenue	2,889	49	5,896
– Fair value change	562	0	
Share of profit from equity-accounted investments	4,055	4,021	101
– Realised revenue	3,956	5,878	67
– Fair value change	99	-1,857	
Income from dividends and other profit shares	1,158	1,962	59
– Dividends	52	44	118
– Profits of subsidiaries	1,106	1,918	58
Total financial income	**14,862**	**52,594**	**28**
Net foreign exchange losses	-13,828	0	
Interest expense	-1,582	-1,231	129
– Interest paid	-1,384	-1,111	125
– Interest expense on lease liabilities	-198	-120	165
Derivative expenses	-281	-8,777	3
– Realised expenses	-281	-2,504	11
– Fair value change	0	-6,273	0
Other financial expenses	-3,516	-3,138	112
Total financial expenses	**-19,207**	**-13,146**	**146**
Net financial result	**-4,345**	**39,448**	

Income tax expense €81,182 thousand

Current income tax amounted to €78,320 thousand, representing 18.0% of profit before tax. Taking into account deferred tax of €2,463 thousand and other income-based taxes of €399 thousand, tax expense recognised in the income statement totalled €81,182 thousand. The effective tax rate was 18.6%.

Property, plant and equipment €610,289 thousand

€ thousand	30 Sep 2026	31 Dec 2025	Index
Land	53,940	53,092	102
Buildings	229,831	232,722	99
Equipment	253,121	260,804	97
Property, plant and equipment being acquired	66,054	56,922	116
Right-of-use assets	7,343	8,305	88
Total property, plant and equipment	**610,289**	**611,845**	**100**

The value of property, plant and equipment accounted for 21% of the Krka balance sheet total. See the 'Investments' section in the business report for details on major investments of Krka.

Intangible assets €40,398 thousand

€ thousand	30 Sep 2026	31 Dec 2025	Index
Concessions, trademarks and licences	26,124	15,740	166
Other intangible assets	5,855	6,672	88
– Long-term deferred operating costs	38	84	45
– Development-related projects	3,884	4,564	85
– Emission coupons	1,933	2,024	96
Intangible assets being acquired	8,419	1,951	432
Total intangible assets	**40,398**	**24,363**	**166**

Intangible assets refer to software and registration documents for new pharmaceuticals.

Loans €127,849 thousand

€ thousand	30 Sep 2026	31 Dec 2025	Index
Non-current loans	**48,215**	**25,504**	**189**
– Loans to subsidiaries	11,100	11,100	100
– Loans to joint ventures	21,136	0	
– Loans to others	15,979	14,404	111
Current loans	**79,634**	**60,509**	**132**
– Portion of non-current loans maturing next year	2,329	2,108	110
– Loans to subsidiaries	8,259	4,734	174
– Loans to others	212	199	107
– Deposits granted to banks	68,000	53,000	128
– Current interest receivable	834	468	178
Total loans	**127,849**	**86,013**	**149**

Investments €265,983 thousand

€ thousand	30 Sep 2026	31 Dec 2025	Index
Non-current investments	**19,405**	**20,059**	**97**
– Investments at fair value through OCI (equity instruments)	19,405	20,059	97
Current investments including derivatives	**246,578**	**257,288**	**96**
– Investments at fair value through profit or loss	246,263	257,288	96
– Derivatives	315	0	
Total investments	**265,983**	**277,347**	**96**

Investments at fair value through OCI comprised €1,771 thousand of investments in shares and interests in companies in Slovenia (end of 2025: €1,557 thousand), and €17,634 thousand of investments in shares and interests in companies outside Slovenia (end of 2025: €18,502 thousand).

The decrease in investments at fair value through profit or loss of €11,025 thousand comprised treasury bill acquisitions totalling €298,875 thousand, disposals of treasury bills totalling €310,000 thousand, and treasury bill revaluation gain totalling €100 thousand.

Inventories — €544,379 thousand

€ thousand	30 Sep 2026	31 Dec 2025	Index
Materials	221,006	237,386	93
Work in progress	125,790	108,427	116
Finished products	116,953	110,352	106
Merchandise	51,572	52,645	98
Advances for inventories	29,058	31,050	94
Total inventories	**544,379**	**539,860**	**101**

Trade and other receivables — €668,183 thousand

€ thousand	30 Sep 2026	31 Dec 2025	Index
Current trade receivables	646,846	560,340	115
– Receivables due from subsidiaries	394,939	313,900	126
– Receivables due from joint ventures	28	0	
– Receivables due from customers other than Krka Group companies	251,879	246,440	102
Current receivables due from others	21,337	11,125	192
Total receivables	**668,183**	**571,465**	**117**

Cash and cash equivalents — €226,411 thousand

€ thousand	30 Sep 2026	31 Dec 2025	Index
Bank balances	226,411	273,658	83
Total cash and cash equivalents	**226,411**	**273,658**	**83**

Bank balances included a deposit of €204,807 thousand with a maturity of up to 90 days (31 December 2025: €246,915 thousand).

Equity — €2,320,264 thousand

€ thousand	30 Sep 2026	31 Dec 2025	Index
Share capital	54,732	54,732	100
Treasury shares	-256,163	-225,047	114
Reserves:	401,784	371,177	108
– Reserves for treasury shares	256,163	225,047	114
– Share premium	105,897	105,897	100
– Legal reserves	14,990	14,990	100
– Statutory reserves	30,000	30,000	100
– Fair value reserve	-5,266	-4,757	111
Retained earnings	2,119,911	2,071,722	102
Total equity	**2,320,264**	**2,272,584**	**102**

Provisions — €132,010 thousand

€ thousand	30 Sep 2026	31 Dec 2025	Index
Non-current provisions	**127,839**	**123,912**	**103**
Provisions for lawsuits	7,400	7,400	100
Provisions for post-employment benefits	99,242	96,588	103
Provisions for other non-current employee benefits	21,197	19,924	106
Current provisions	**4,171**	**18,671**	**22**
Total provisions	**132,010**	**142,583**	**93**

Deferred income — €2,201 thousand

€ thousand	30 Sep 2026	31 Dec 2025	Index
Grants received from the European Regional Development Fund and the budget of the Republic of Slovenia intended for the production of pharmaceuticals in the new Notol 2 plant	481	520	93
Property, plant and equipment received free of charge	4	6	67
Emission coupons	6	10	60
Subsidy for purchase of joinery	86	86	100
Grants received from the European Regional Development Fund (Farma GRS)	1,119	1,243	90
Subsidy for upgrading trucks	66	35	189
Subsidy for electricity production from renewable energy installations	439	463	95
Total deferred income	**2,201**	**2,363**	**93**

Trade payables — €210,009 thousand

€ thousand	30 Sep 2026	31 Dec 2025	Index
Current trade payables	**210,009**	**160,231**	**131**
Payables to subsidiaries	86,307	63,520	136
Payables to joint ventures	28	0	
Payables to domestic suppliers	47,520	42,327	112
Payables to foreign suppliers	76,154	54,384	140
Total trade payables	**210,009**	**160,231**	**131**

Borrowings — €48,997 thousand

€ thousand	30 Sep 2026	31 Dec 2025	Index
Current borrowings	**48,997**	**34,376**	**143**
– Borrowings from subsidiaries	48,331	34,278	141
– Current interest payable	666	98	680
Total borrowings	**48,997**	**34,376**	**143**

Current contract liabilities — €19,932 thousand

€ thousand	30 Sep 2026	31 Dec 2025	Index
Refund liabilities	**13,070**	**19,373**	**67**
– Bonuses and volume rebates	13,070	19,373	67
Contract liabilities	**6,862**	**4,399**	**156**
– Advances from Krka Group customers	0	342	0
– Advances from other customers	6,862	4,057	169
Total current contract liabilities	**19,932**	**23,772**	**84**

Other current liabilities — €92,013 thousand

€ thousand	30 Sep 2026	31 Dec 2025	Index
Payables to employees – gross salaries, other receipts and charges	89,111	88,225	101
Derivatives	0	247	0
Other	2,902	1,786	162
Total other current liabilities	**92,013**	**90,258**	**102**

Contingent liabilities and commitments €26,215 thousand

€ thousand	30 Sep 2026	31 Dec 2025	Index
Guarantees issued	17,201	25,192	68
Contingent liabilities	8,149	7,858	104
Other	865	853	101
Total contingent liabilities	**26,215**	**33,903**	**77**

Fair value

€ thousand	30 Sep 2026		31 Dec 2025	
	Carrying amount	Fair value	Carrying amount	Fair value
Non-current financial assets				
Loans	48,215		25,504	
Investments at fair value through OCI (equity instruments)	19,405	19,405	20,059	20,059
Current financial assets				
Loans	79,634		60,509	
Investments at fair value through profit or loss	246,263	246,263	257,288	257,288
Derivatives	315	315	0	0
Trade receivables	646,846		560,340	
Cash and cash equivalents	226,411		273,658	
Non-current financial liabilities				
Lease liabilities	-5,960		-6,646	
Current financial liabilities				
Borrowings	-48,997		-34,376	
Derivatives	0	0	-247	-247
Lease liabilities	-1,567		-1,717	
Trade payables to suppliers, subsidiaries and joint ventures, excluding advances	-210,009		-160,231	
Contract liabilities excluding advances	-13,070		-19,373	
Other liabilities excluding amounts owed to the State, to employees, and advances	-854		-1,046	
Total	**986,632**	**265,983**	**973,722**	**277,100**

In terms of fair value, assets and liabilities are classified into three levels:

- Level 1 – assets at market price;
- Level 2 – assets not classified within level 1 and the value of which is determined directly or indirectly based on observable market data;
- Level 3 – assets, the value of which cannot be determined using observable market data.

Assets at fair value

€ thousand	30 Sep 2026				31 Dec 2025			
	Level 1	Level 2	Level 3	Total	Level 1	Level 2	Level 3	Total
Assets at fair value								
Investments at fair value through OCI (equity instruments)	18,019	0	1,386	19,405	18,673	0	1,386	20,059
Investments at fair value through profit or loss	246,263	0	0	246,263	257,288	0	0	257,288
Derivatives	0	0	315	315	0	0	0	0
Total assets at fair value	**264,282**	**0**	**1,701**	**265,983**	**275,961**	**0**	**1,386**	**277,347**

STATEMENT OF COMPLIANCE

The Management Board of Krka, d. d., Novo mesto hereby states that the condensed financial statements of Krka and the condensed consolidated financial statements of the Krka Group for the period ended 30 September 2026 have been prepared so as to provide a true and fair view of the financial position and operating results of the Krka Group and Krka. The condensed financial statements for the period January to September 2026 have been prepared using the same accounting policies as for the 2025 annual financial statements of the Krka Group and Krka.

The condensed financial statements for the period ended 30 September 2026 have been prepared pursuant to *IAS 34 – Interim Financial Reporting* and have to be read in conjunction with the annual financial statements prepared for the financial year ended 31 December 2025.


The Management Board is responsible for taking the measures required to preserve the assets of the Krka Group and Krka, and to prevent and detect fraud and other forms of misconduct.

The Management Board states that all transactions between Krka Group subsidiaries have been executed according to the concluded purchase contracts, using market prices of products and services. No significant business transactions were concluded with other related parties.

Novo mesto, 3 November 2026



Jože Colarič
President of the Management Board and CEO



Dr Aleš Rotar
Member of the Management Board



Dr Vinko Zupančič
Member of the Management Board



David Bratož
Member of the Management Board



Milena Kastelic
Member of the Management Board – Worker Director